Advances in clinical NK cell studies: Donor selection, manufacturing and quality control

Natural killer (NK) cells are increasingly used in clinical studies in order to treat patients with various malignancies. The following review summarizes platform lectures and 2013–2015 consortium meetings on manufacturing and clinical use of NK cells in Europe and United States. A broad overview of...

Descripción completa

Detalles Bibliográficos
Autores principales: Koehl, U., Kalberer, C., Spanholtz, J., Lee, D. A., Miller, J. S., Cooley, S., Lowdell, M., Uharek, L., Klingemann, H., Curti, A., Leung, W., Alici, E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2015
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4839369/
https://www.ncbi.nlm.nih.gov/pubmed/27141397
http://dx.doi.org/10.1080/2162402X.2015.1115178
_version_ 1782428129637171200
author Koehl, U.
Kalberer, C.
Spanholtz, J.
Lee, D. A.
Miller, J. S.
Cooley, S.
Lowdell, M.
Uharek, L.
Klingemann, H.
Curti, A.
Leung, W.
Alici, E.
author_facet Koehl, U.
Kalberer, C.
Spanholtz, J.
Lee, D. A.
Miller, J. S.
Cooley, S.
Lowdell, M.
Uharek, L.
Klingemann, H.
Curti, A.
Leung, W.
Alici, E.
author_sort Koehl, U.
collection PubMed
description Natural killer (NK) cells are increasingly used in clinical studies in order to treat patients with various malignancies. The following review summarizes platform lectures and 2013–2015 consortium meetings on manufacturing and clinical use of NK cells in Europe and United States. A broad overview of recent pre-clinical and clinical results in NK cell therapies is provided based on unstimulated, cytokine-activated, as well as genetically engineered NK cells using chimeric antigen receptors (CAR). Differences in donor selection, manufacturing and quality control of NK cells for cancer immunotherapies are described and basic recommendations are outlined for harmonization in future NK cell studies.
format Online
Article
Text
id pubmed-4839369
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-48393692016-05-02 Advances in clinical NK cell studies: Donor selection, manufacturing and quality control Koehl, U. Kalberer, C. Spanholtz, J. Lee, D. A. Miller, J. S. Cooley, S. Lowdell, M. Uharek, L. Klingemann, H. Curti, A. Leung, W. Alici, E. Oncoimmunology Review Natural killer (NK) cells are increasingly used in clinical studies in order to treat patients with various malignancies. The following review summarizes platform lectures and 2013–2015 consortium meetings on manufacturing and clinical use of NK cells in Europe and United States. A broad overview of recent pre-clinical and clinical results in NK cell therapies is provided based on unstimulated, cytokine-activated, as well as genetically engineered NK cells using chimeric antigen receptors (CAR). Differences in donor selection, manufacturing and quality control of NK cells for cancer immunotherapies are described and basic recommendations are outlined for harmonization in future NK cell studies. Taylor & Francis 2015-11-11 /pmc/articles/PMC4839369/ /pubmed/27141397 http://dx.doi.org/10.1080/2162402X.2015.1115178 Text en © 2016 The Author(s). Published with license by Taylor & Francis Group, LLC http://creativecommons.org/licenses/by-nc/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. The moral rights of the named author(s) have been asserted.
spellingShingle Review
Koehl, U.
Kalberer, C.
Spanholtz, J.
Lee, D. A.
Miller, J. S.
Cooley, S.
Lowdell, M.
Uharek, L.
Klingemann, H.
Curti, A.
Leung, W.
Alici, E.
Advances in clinical NK cell studies: Donor selection, manufacturing and quality control
title Advances in clinical NK cell studies: Donor selection, manufacturing and quality control
title_full Advances in clinical NK cell studies: Donor selection, manufacturing and quality control
title_fullStr Advances in clinical NK cell studies: Donor selection, manufacturing and quality control
title_full_unstemmed Advances in clinical NK cell studies: Donor selection, manufacturing and quality control
title_short Advances in clinical NK cell studies: Donor selection, manufacturing and quality control
title_sort advances in clinical nk cell studies: donor selection, manufacturing and quality control
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4839369/
https://www.ncbi.nlm.nih.gov/pubmed/27141397
http://dx.doi.org/10.1080/2162402X.2015.1115178
work_keys_str_mv AT koehlu advancesinclinicalnkcellstudiesdonorselectionmanufacturingandqualitycontrol
AT kalbererc advancesinclinicalnkcellstudiesdonorselectionmanufacturingandqualitycontrol
AT spanholtzj advancesinclinicalnkcellstudiesdonorselectionmanufacturingandqualitycontrol
AT leeda advancesinclinicalnkcellstudiesdonorselectionmanufacturingandqualitycontrol
AT millerjs advancesinclinicalnkcellstudiesdonorselectionmanufacturingandqualitycontrol
AT cooleys advancesinclinicalnkcellstudiesdonorselectionmanufacturingandqualitycontrol
AT lowdellm advancesinclinicalnkcellstudiesdonorselectionmanufacturingandqualitycontrol
AT uharekl advancesinclinicalnkcellstudiesdonorselectionmanufacturingandqualitycontrol
AT klingemannh advancesinclinicalnkcellstudiesdonorselectionmanufacturingandqualitycontrol
AT curtia advancesinclinicalnkcellstudiesdonorselectionmanufacturingandqualitycontrol
AT leungw advancesinclinicalnkcellstudiesdonorselectionmanufacturingandqualitycontrol
AT alicie advancesinclinicalnkcellstudiesdonorselectionmanufacturingandqualitycontrol

Ejemplares similares